RHON-KLINIKUM AG, one of Germany’s largest healthcare providers, announced a stable financial performance for the first half of 2026, with revenues slightly up at EUR 863.6 million and a significant increase in patient numbers. The company’s EBITDA rose to EUR 57.0 million from EUR 46.7 million in the same period last year, and consolidated profit reached EUR 22.5 million, up from EUR 14.7 million. The results were partly shaped by immediate transformation costs aimed at offsetting higher personnel and material costs from previous years.
The Group treated 513,700 patients on an outpatient and inpatient basis from January to June, a 9% increase compared to 471,295 in the first half of 2025. This growth reflects ongoing investments in medical technology and the expansion of regional healthcare networks. In Hesse, Universitatsklinikum Marburg and Lungenfachklinik Immenhausen have formed a strategic partnership to improve lung patient care. In Brandenburg, a new child protection emergency service at the RHON-KLINIKUM Frankfurt (Oder) site has been launched, supported by cooperation agreements with the City of Frankfurt (Oder) and the District of Oder-Spree to coordinate rapid help for children and adolescents.
Dr. Gunther K. WeiB, member of the Board of Management, emphasized the importance of regional networks: “Regional networks form a vital and essential part of any future healthcare system. Rigid sectoral boundaries make it more difficult to provide patients with the care they need and saddle our healthcare system with unnecessary costs. It is only when general practitioners, specialists, medical facilities, nurses and therapists work together as a team that we can pool our resources efficiently. In the face of mounting pressures, such collaboration across providers is the only way to ensure comprehensive and high-quality care to patients, especially in rural areas.”
However, the company faces headwinds from recent legislation. The Statutory Health Insurance Contribution Rate Stabilization Act (GKV-Beitragsstabilisierungsgesetz) and the Hospital Reform Adjustment Act (Krankenhausreformanpassungsgesetz) are intended to improve quality and efficiency but impose additional financial burdens on hospitals. Dr. Stefan Stranz, member of the Board of Management, criticized the reforms: “The Statutory Health Insurance Contribution Rate Stabilization Act imposes further burdens on hospitals. Instead of reducing bureaucracy and refocusing on patient care, the reform saddles already overburdened hospitals with even more documentation requirements, excessive budget cuts, and financial risks.”
Looking ahead, RHON-KLINIKUM AG forecasts full-year revenues of EUR 1.7 billion (plus or minus 5%) and EBITDA between EUR 110 million and EUR 125 million. The company also expects moderate improvements in non-financial indicators such as number of cases and cost weights. However, the forecast is subject to significant uncertainties due to ongoing regulatory changes, global crises, and economic volatility. The company remains committed to its strategy of expanding regional health networks and improving patient care despite these challenges.
For more details, the full Interim Report for the first half of 2026 is available on the company’s website. RHON-KLINIKUM AG operates five hospitals, including the Giessen and Marburg University Hospitals (UKGM), and employs over 19,100 staff, treating around 938,000 patients annually. It is part of the ASKLEPIOS Group.
